📰 Nasdaq Bpmc News
Nasdaq Bpmc News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Bpmc. Real-time updates on events, politics, business and more.
May 7, 2024
Blueprint Medicines (NASDAQ:BPMC – Free Report) had its price objective hoisted by Citigroup from $65.00 to $76.00 in a report issued on Friday, Benzinga reports. They currently have a sell rating on the biotechnology company’s stock. Other equities research analysts have also recently issued reports about the stock. Stifel Nicolaus upped their price objective on […]
May 6, 2024
Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) CFO Michael Landsittel sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $105.00, for a total value of $1,050,000.00. Following the transaction, the chief financial officer now owns 47,286 shares of […]
May 5, 2024
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) had its price objective increased by investment analysts at HC Wainwright from $125.00 to $135.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential […]
May 4, 2024
Blueprint Medicines (NASDAQ:BPMC – Free Report) had its price objective increased by JMP Securities from $114.00 to $125.00 in a report issued on Friday morning, Benzinga reports. They currently have a market outperform rating on the biotechnology company’s stock. BPMC has been the subject of a number of other research reports. Barclays lifted their target […]
May 3, 2024
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) had its price target boosted by equities research analysts at Barclays from $70.00 to $75.00 in a report released on Friday, Benzinga reports. The firm presently has an “equal weight” rating on the biotechnology company’s stock. Barclays‘s price target would suggest a potential downside of 30.23% from the […]
May 3, 2024
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) had its price objective lifted by investment analysts at Barclays from $70.00 to $75.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm presently has an “equal weight” rating on the biotechnology company’s stock. Barclays‘s price target would indicate a potential downside […]
May 2, 2024
Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report)’s share price hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $107.56 and last traded at $107.00, with a volume of 391291 shares. The stock had previously closed at $94.86. Wall Street Analyst Weigh In A number of brokerages […]
April 30, 2024
Wedbush reissued their outperform rating on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a report issued on Friday, Benzinga reports. Wedbush currently has a $110.00 target price on the biotechnology company’s stock. Several other equities analysts have also recently commented on the company. Needham & Company LLC reiterated a buy rating and set […]
April 3, 2024
Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) CFO Michael Landsittel sold 5,000 shares of Blueprint Medicines stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $95.00, for a total value of $475,000.00. Following the completion of the transaction, the chief financial officer now owns 47,286 shares […]
March 29, 2024
Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) Director Jeffrey W. Albers sold 11,033 shares of the stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $90.69, for a total value of $1,000,582.77. Following the transaction, the director now directly owns 165,017 shares of the company’s stock, […]